47-3552922

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-1

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

BLUEJAY DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter)

3841

Delaware

(State or other juris	sdiction of	(Primary Standard Industrial	(I.R.S. Employer	
incorporation or org	ganization)	Classification Code Number)	Identification Number)	
		360 Massachusetts Avenue, Suite 203		
		Acton, MA 01720		
		Telephone: (844) 327-7078		
(Address, In	cluding Zip Code, and Tele	phone Number, Including Area Code, of Reg	gistrant's Principal Executive Offices)	
(,	8 F,	F	,	
		Neil Dey		
		Chief Executive Officer and President		
		360 Massachusetts Avenue, Suite 203		
		Acton, MA 01720		
(NI.		Telephone: (844) 327-7078	Color (Area Fra Constant)	
(INai	ne, Address, Including Zip	Code, and Telephone Number, Including Are	a Code, of Agent For Service)	
		Copies to:		
-	ı V. De Martino, Esq.		Robert F. Charron, Esq.	
	avas Pavri, Esq.		enoff Grossman & Schole LLP	
	chiff Hardin LLP		1345 Avenue of the Americas	
9	01 K Street NW		New York, New York 10105	
.	Suite 700		Telephone: (212) 931-8704	
	Shington, DC 20001			
тетер	hone: (202) 724.6848			
	ring registered on this Form		ter the effective date of this registration statem basis pursuant to Rule 415 under the Securities A	
		or an offering pursuant to Rule 462(b) under of the earlier effective registration statement	the Securities Act, please check the following bofor the same offering. \boxtimes 333-260029	X
		suant to Rule 462(c) under the Securities Act stration statement for the same offering. \Box	, check the following box and list the Securities A	ct
		suant to Rule 462(d) under the Securities Act istration statement for the same offering. \Box	c, check the following box and list the Securities A	\ Ct
		nark if the registrant has elected not to use thoursuant to Section 7(a)(2)(B) of the Securities	be extended transition period for complying with a ses Act. \square	ıny
	ee the definitions of "large		on-accelerated filer, a smaller reporting company er reporting company" and "emerging growth	or an
Large accelerated filer			Accelerated filer	
Non-accelerated filer	\boxtimes		Smaller reporting company	\boxtimes
			Emerging growth company	\boxtimes

CALCULATION OF REGISTRATION FEE

Title of each Class of Securities to be Registered	Ā	Maximum Aggregate Offering rice ⁽¹⁾⁽²⁾⁽³⁾	Amount of Registration Fee
Units: ⁽⁷⁾	\$	4,140,000	\$ 383.78
Common stock, par value \$0.0001 per share ⁽⁴⁾		_	_
Warrants to purchase common stock ⁽⁴⁾		_	_
Shares of common stock issuable upon exercise of the Class A Warrants	\$	2,898,000	\$ 268.64
Shares of common stock issuable upon exercise of the Class B Warrants	\$	4,140,000	\$ 383.78
Series E Convertible Preferred Stock ⁽⁶⁾		_	_
Shares of common stock underlying the Series E Convertible Preferred Stock		_	_
Underwriter's warrants ⁽⁵⁾		_	_
Common stock underlying Underwriters' warrants ⁽⁵⁾	\$	258,750	\$ 23.99
Total	\$	11,436,750	\$ 1,060.19(9)

- (1) Estimated solely for the purpose of calculating the amount of the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended.
- (2) Pursuant to Rule 416, the securities being registered hereunder include such indeterminate number of additional securities as may be issuable to prevent dilution resulting from stock splits, stock dividends or similar transactions.
- (3) Includes the price of additional shares of common stock and warrants to purchase shares of common stock that the underwriters have the option to purchase to cover overallotments, if any.
- (4) Included in the price of the units. No separate registration fee is required pursuant to Rule 457(g) under the Securities Act.
- (5) Estimated solely for the purposes of calculating the registration fee pursuant to Rule 457(g) under the Securities Act. We have calculated the proposed maximum aggregate offering price of the common stock underlying the underwriter's warrants by assuming that such warrants are exercisable at a price per share equal to 125% of the public offering price of the common stock in the units sold in this offering.
- (6) The maximum aggregate offering price of the common stock proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any Series E Convertible Preferred Stock offered and sold in the offering.
- (7) Each unit includes (i) one share of common stock (or, at the purchaser's election, one share of Series E Convertible Preferred Stock), (ii) one Class A Warrant, and (iii) one Class B Warrant.
- (8) Represents 4,500,000 shares of common stock at an assumed price of \$10.00, the public offering price.
- (9) The Registrant previously registered securities having a proposed maximum aggregate offering price of \$102,183,750 on its Registration Statement on Form S-1, as amended (File No. 333-260029) which was declared effective by the Securities and Exchange Commission on November 9, 2021. In accordance with Rule 462(b) under the Securities Act, an additional number of securities having a proposed maximum offering price of \$11,436,750 is hereby registered.

The Registration Statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) under the Securities Act of 1933, as amended.

EXPLANATORY NOTE

This Registration Statement on Form S-1 is being filed with respect to the registration of 414,000 additional Units of Bluejay Diagnostics, Inc., a Delaware corporation (the "Registrant"), pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and General Instruction V to Form S-1. Each Unit consists of (a) one share of Registrant common stock (or, at the purchaser's election, one share of Series E Convertible Preferred Stock), (b) one Class A warrant to purchase one share of Registrant common stock at an exercise price equal to \$7.00 per share, exercisable until the fifth anniversary of the issuance date, and (c) one Class B warrant to purchase one share of Registrant common stock at an exercise price equal to \$10.00 per share, exercisable until the fifth anniversary of the issuance date. In addition, this Registration Statement is being filed with respect to the registration of a warrant to purchase up to 20,700 shares of common stock that may be issued to the representative of the underwriters (or its designees) in the offering subject to the Registration Statement. This Registration Statement relates to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-260029) (the "Prior Registration Statement"), initially filed by the Registrant on October 4, 2021 and declared effective by the Securities and Exchange Commission (the "Commission") on November 9, 2021. The required opinion of counsel and related consent and accountant's consent are attached hereto and filed herewith. Pursuant to Rule 462(b), the contents of the Prior Registration Statement, including the exhibits thereto, are incorporated by reference into this Registration Statement.

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 16. Exhibits and Financial Statement Schedules.

- (a) Exhibits. All exhibits filed with or incorporated by reference in the Registration Statement on Form S-1 (SEC File No. 333-260029) are incorporated by reference into, and shall be deemed a part of, this Registration Statement, and the following additional exhibits are filed herewith, as part of this Registration Statement:
- 5.1 Opinion of Schiff Hardin LLP
- 23.1 Consent of Wolf and Company, P.C.
- 23.2 Consent of Schiff Hardin LLP (included on Exhibit 5.1).

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, each registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Acton, Commonwealth of Massachusetts, on the 9th day of November, 2021.

BLUEJAY DIAGNOSTICS INC.

By: /s/ Neil Dey
Name: Neil Dey

Title: Chief Executive Officer and President

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Name	Position	Date
/s/ Neil Dey	President, Chief Executive Officer and Director	November 9, 2021
Neil Dey		
/s/ Gordon Kinder	Chief Financial Officer	November 9, 2021
Gordon Kinder	(Principal Financial Officer and Principal Accounting Officer)	
*	Chairman of the Board	November 9, 2021
Douglas Wurth		
*	Director	November 9, 2021
Svetlana Dey		
*	Director	November 9, 2021
Donald R. Chase		
*	Director	November 9, 2021
Fred S. Zeidman		
* Pursuant to power of attorne	ey	
By: /s/ Gordon Kinder		
Gordon Kinder		
Attorney-in-fact		

BlueJay Diagnostics, Inc. 360 Massachusetts Avenue, Suite 203 Acton, MA 01720

Re: Form S-1 Registration Statement

Ladies and Gentlemen:

We have acted as counsel to BlueJay Diagnostics, Inc., a Delaware corporation (the "<u>Company</u>"), in connection with the Registration Statement on Form S-1 (as amended, the "Registration Statement"), filed by the Company on November 9, 2021 with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Securities Act").

The Registration Statement incorporates by reference the registration statement on Form S-1 (Registration No. 333-260029) initially filed with the Commission on October 4, 2021, as amended to date (the "Prior Registration Statement"), which was declared effective by the Commission on November 9, 2021. The Registration Statement relates to the registration, pursuant to Rule 462(b) under the Securities Act, of the offer and sale of: (A) \$4,140,000 of units (the "Units") of securities of the Company, with each Unit consisting of (a) one share of common stock, par value \$0.0001 per share, of the Company ("Common Stock") (or, to each purchaser whose purchase of shares of Common Stock in such offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% of the Company's outstanding Common Stock immediately following the consummation of such offering, a share of the Company's Series E Preferred Stock (the "Preferred Stock") (and the shares of Common Stock issuable from time to time upon conversion of the Preferred Stock), in lieu of a share of Common Stock), (b) one Class A warrant to purchase one share of Common Stock (the "Class B Warrants,") and (c) one Class B warrant to purchase one share of Common Stock (the "Class B Warrants,") and collectively, with the Class A Warrants, the "Warrants")); and (B) \$258,750 of underwriters' warrants to purchase shares of Common Stock (and the shares of Common Stock issuable from time to time upon exercise of the Underwriters' Warrants) (the "Underwriters' Warrants"). Each share of Preferred Stock will be convertible into one share of Common Stock. The Common Stock, Preferred Stock, Warrants, and Underwriters' Warrants are referred to herein collectively as the "Securities." The Securities are being sold to the several underwriters named in, and pursuant to, an underwriting agreement among the Company and such underwriters ("Underwriting Agreement").

In connection with our opinion, we have examined the Registration Statement, including the exhibits thereto, the form of Underwriters' Warrant, and such other documents, corporate records and instruments, and have examined such laws and regulations, as we have deemed necessary for the purposes of this opinion. In making our examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity with the originals of all documents submitted to us as copies and the legal capacity of all natural persons. As to matters of fact material to our opinions in this letter, we have relied on certificates and statements from officers and other employees of the Company, public officials and other appropriate persons.

Based on the foregoing and subject to the qualifications set forth below, we are of the opinion that:

- 1. The Securities have been duly authorized for issuance by all necessary corporate action by the Company.
- 2. The shares of Common Stock, when issued and sold as described in the Registration Statement, will be validly issued, fully paid and non-assessable.
- 3. The shares of Preferred Stock, if purchased in lieu of Common Stock, when issued and sold as described in the Registration Statement, will be validly issued, fully paid and non-assessable.
- 4. Provided that the Units, the Warrants and Underwriters' Warrants have been duly executed and delivered by the Company and duly delivered to the purchasers or underwriters, such Units, Warrants and Underwriters' Warrants, when issued as contemplated in the Registration Statement, will be valid and binding obligations of the Company.

- 5. The shares of Common Stock issuable pursuant to each of the Class A Warrants, Class B Warrants and Underwriter's Warrants, upon payment to the Company of the required consideration, and when issued and sold by the Company and paid for in accordance with the terms of the Class A Warrants, Class B Warrants, or Underwriters' Warrants, as applicable, and as described in the Registration Statement, will be validly issued, fully paid and non-assessable.
- 6. The shares of Common Stock issuable pursuant to the conversion of the Preferred Stock, and when issued by the Company in accordance with the terms of the Preferred Stock, as described in the Registration Statement, will be validly issued, fully paid and non-assessable.

The opinions set forth above are subject to the following qualifications:

- A. The opinion expressed herein with respect to the legality, validity, binding nature and enforceability of the Units, Warrants and Underwriters' Warrant is subject to (i) applicable laws relating to bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer or other similar laws affecting creditors' rights generally, whether now or hereafter in effect and (ii) general principles of equity, including, without limitation, concepts of materiality, laches, reasonableness, good faith and fair dealing and the principles regarding when injunctive or other equitable remedies will be available (regardless of whether considered in a proceeding at law or in equity).
- B. The foregoing opinions are limited to the laws of the State of New York and the General Corporation Law of Delaware, and we express no opinion as to the laws of any other jurisdiction.

The opinions expressed in this opinion letter are as of the date of this opinion letter only and as to laws covered hereby only as they are in effect on that date, and we assume no obligation to update or supplement such opinion to reflect any facts or circumstances that may come to our attention after that date or any changes in law that may occur or become effective after that date. The opinions herein are limited to the matters expressly set forth in this opinion letter, and no opinion or representation is given or may be inferred beyond the opinions expressly set forth in this opinion letter.

We hereby consent to the filing of this opinion with the Commission as an exhibit to the Registration Statement and to the use of this firm's name under the caption "Legal Matters" in the Registration Statement. In giving this consent, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.

Very truly yours,

/s/ Schiff Hardin LLP

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in this Registration Statement on Form S-1 of Bluejay Diagnostics, Inc. filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, of our report dated June 30, 2021, relating to the financial statements of Bluejay Diagnostics, Inc., appearing in the Prospectus, which is incorporated by reference in this Registration Statement.

We also consent to the reference to our Firm under the caption "Experts" in such Prospectus.

/s/ Wolf & Company, P.C.

Wolf & Company, P.C. Boston, Massachusetts November 9, 2021